Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade
Journal of Gastroenterology and Hepatology · 2025-02 · 40 (2) · 413-420
DOI: 10.1111/jgh.16829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 04.12.2024. Verfasst von Amir Ben-Tov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Eosinophilia, Gastritis, Eosinophilic Esophagitis, Enteritis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Eosinophilic gastrointestinal disorders (EGIDs) are primary immune‐mediated disorders, with significant morbidity and long‐term sequelae. Temporal trends in incidence and prevalence are on the rise, but studies outside Europe and North America are sparse.
Methods
Based on retrospective Electronic Medical Records (EMR) data, we studied a large population cohort during the years 2014–2021 of all patients diagnosed with EGIDs. Incidence rate and prevalence were calculated for each year during the study cohort stratified by disease location, age, and sex.
Results
Between 2014 and 2021, among a population of 2.4 million persons, the incidence rate of EGIDs tripled from 2.51 (95% CI: 1.78–3.23) to 7.88 (95% CI: 6.75–9.01) per 100 000 person‐years. Most (85.1%) were patients with eosinophilic esophagitis (EoE). The increased temporal trend was almost identical among all subgroups, including patients with EoE, patients with non‐EoE EGIDs, and patients with EGIDs with esophageal involvement. The prevalence of EGIDs increased from 14.53 (95% CI: 12.80–16.26) to 51.43 (95% CI: 48.60–54.26) per 100 000 persons. In 2021, at the end of the study, the prevalence of EoE was 39.54 (95% CI: 37.05–42.02) per 100 000 persons, and the prevalence of non‐EoE EGID was 11.89 (95% CI: 10.53–13.26) per 100 000 persons.
Conclusions
The incidence and prevalence of EGIDs in Israel have risen steeply during the last decade. The main contribution came from the increased incidence rate of patients with EoE. By the end of the surveillance period, the increased temporal trends did not reach a plateau.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
- Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Kfar-Saba, Israel.
ORCID-Profile: Amir Ben-Tov
Förderung
- AstraZeneca
Zitieren
APA
Ben-Tov, A., Melzer-Cohen, C., Yahalom, R., Yarden, A., Livnat, I., Patalon, T., & Gazit, S. (2025). Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade. Journal of Gastroenterology and Hepatology, 40(2), 413-420. https://doi.org/10.1111/jgh.16829
Vancouver
Ben-Tov A, Melzer-Cohen C, Yahalom R, Yarden A, Livnat I, Patalon T, et al. Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade. Journal of Gastroenterology and Hepatology. 2025;40(2):413-420. doi:10.1111/jgh.16829
BibTeX
@article{BenTov2025,
author = {Ben-Tov, Amir and Melzer-Cohen, Cheli and Yahalom, Roni and Yarden, Adva and Livnat, Idit and Patalon, Tal and Gazit, Sivan},
title = {Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
volume = {40},
number = {2},
pages = {413--420},
doi = {10.1111/jgh.16829}
}
EUVIMED